P2RY12 and myocardial infarction: In fact, the combination therapy of apixaban with P2Y12 inhibitors was associated with a lower risk of thrombolysis in myocardial infarction major and minor bleeding, trial-defined primary bleeding events, and intracranial hemorrhage compared with the combination therapy of P2Y12 inhibitors with warfarin in meta-analysis (19), and the risk of IOHs with combination therapy of apixaban requires further investigation.